BioAtla
BCAB
79 hedge funds and large institutions have $87.6M invested in BioAtla in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 26 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 16
15% more call options, than puts
Call options by funds: $147K | Put options by funds: $128K
0.09% less ownership
Funds ownership: 1.47% → 1.37% (-0.09%)
13% less funds holding
Funds holding: 91 → 79 (-12)
46% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 26
69% less capital invested
Capital invested by funds: $279M → $87.6M (-$191M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$12.7M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.48M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.85M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$16.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.28M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.36M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$4.51M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
UBS Group
Zurich,
Switzerland
| – | -$25.3K | -61 | Closed |
|
|
TWA
102
TCI Wealth Advisors
Tucson,
Arizona
| – | -$1.97K | -5 | Closed |
|
103
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$180 | -1 | Closed |
|
BCAB Hedge Fund Activity: Q1 2023 in Review
79 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q1 2023, worth a combined $87.6M — down 69% from $279M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of BCAB and 14 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 33 added.
The largest buyer was OrbiMed, adding an estimated $12.7M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $16.4M sold.
- 79 institutional investors held BioAtla (BCAB) as of Q1 2023, down from 91 in Q4 2022.
- Funds reported $87.6M of BioAtla stock for Q1 2023, down 69% quarter-over-quarter.
- 14 funds opened new BioAtla positions in Q1 2023 and 26 closed out, a net change of -12 holders.
- The largest BioAtla buyer in Q1 2023 was OrbiMed, an estimated $12.7M added.
- The largest BioAtla seller in Q1 2023 was Janus Henderson Group, an estimated $16.4M sold.
Based on aggregated 13F filings for Q1 2023.